

CITATION REPORT

List of articles citing

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

DOI: 10.1016/s0149-2918(00)83039-8
Clinical Therapeutics, 2000, 22, 1395-409.

Source: <https://exaly.com/paper-pdf/32018516/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
338	Hepatotoxicity with thiazolidinediones: is it a class effect?. 2001 , 24, 873-88		100
337	A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , 2001 , 23, 1792-823; discussion 1791	3.5	119
336	Oral therapies for diabetic hyperglycemia. 2001 , 30, 909-33		53
335	Actos (pioglitazone): a new treatment for type 2 diabetes. 2001 , 62, 411-6		2
334	Review: Thiazolidinediones today. 2001 , 1, 7-13		22
333	Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. 2002 , 4, 145-51		28
332	Insulin-sensitizing agents--thiazolidinediones (glitazones). 2002 , 18 Suppl 1, s31-9		16
331	Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. 2002 , 34, 589-95		62
330	Plasma lipids and antidiabetic agents: a brief overview. 2002 , 2, 40-43		10
329	Oral antihyperglycemic therapy for type 2 diabetes: scientific review. 2002 , 287, 360-72		789
328	Multiple drug targets in the management of type 2 diabetes. 2002 , 3, 203-21		25
327	Counseling patients with type 2 diabetes and insulin resistance in the outpatient setting. 2002 , 28, 938-43, 947-50, 952-4 passim		3
326	Pioglitazone [current profile. 2002 , 2, S18-S23		2
325	Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. 2002 , 20 Suppl 1, 31-42		22
324	Metabolic and additional vascular effects of thiazolidinediones. 2002 , 62, 1463-80		222
323	Thiazolidinediones. 2002 , 22, 485-505		18
322	Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. 2002 , 18, 363-70		38

321	New solutions for type 2 diabetes mellitus: the role of pioglitazone. 2002 , 20 Suppl 1, 1-9	13
320	The role of models within economic analysis: focus on type 2 diabetes mellitus. 2002 , 20 Suppl 1, 11-9	22
319	Management of rosiglitazone-induced edema: two case reports and a review of the literature. 2002 , 4, 505-14	25
318	Does hypertriglyceridemia present an indication for pioglitazone therapy in diabetes?. 2002 , 4, 153-5	1
317	Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. 2002 , 13, 428	102
316	Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. <i>Clinical Therapeutics</i> , 2002 , 24, 378-96	3.5 149
315	Thiazolidinediones and type 2 diabetes: new drugs for an old disease. 2002 , 176, 381-6	48
314	Treating dual defects in diabetes: insulin resistance and insulin secretion. 2002 , 59 Suppl 9, S9-13	7
313	Where thiazolidinediones will fit. 2002 , 18 Suppl 2, S30-5	6
312	Differentiating members of the thiazolidinedione class: a focus on efficacy. 2002 , 18 Suppl 2, S16-22	25
311	Differentiating members of the thiazolidinedione class: a focus on safety. 2002 , 18 Suppl 2, S23-9	150
310	Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. 2002 , 4, 514-21	27
309	Redefining the clinical management of type 2 diabetes: matching therapy to pathophysiology. 2002 , 32 Suppl 3, 46-53	23
308	Effects of combined pioglitazone and metformin on diabetes and obesity in Wistar fatty rats. 2002 , 29, 269-74	10
307	Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. 2003 , 17, 211-7	27
306	Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. 2003 , 91, 18E-23E	83
305	Thiazolidinediones: tentative steps forward. 2003 , 20, 309-311	
304	Three years is not a long time in which there can be substantial changes. 2003 , 20, 311-312	

303	Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. 2003 , 78, 459-67		50
302	Tiazolidinadionas: efecto de la pioglitazona sobre la hiperglucemia, la dislipidemia y el riesgo cardiovascular. 2003 , 203, 33-40		
301	Diabetes mellitus and pharmacological therapy. 2003 , 20, 635-53		
300	Current management strategies for coexisting diabetes mellitus and obesity. 2003 , 63, 1165-84		65
299	Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. 2003 , 63, 1373-405		217
298	Metformin: new understandings, new uses. 2003 , 63, 1879-94		233
297	Postmarketing surveillance study of the efficacy and tolerability of pioglitazone in insulin-resistant patients with type 2 diabetes mellitus in general practice. 2003 , 23, 725-34		1
296	Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes. 2003 , 4, 1417-30		17
295	Free fatty acids and type 2 diabetes mellitus. 2003 , 115 Suppl 8A, 29S-36S		73
294	Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. <i>Clinical Therapeutics</i> , 2003 , 25 Suppl B, B4-31	3-5	48
293	Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. <i>Clinical Therapeutics</i> , 2003 , 25 Suppl B, B47-63	3-5	39
292	Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. <i>Clinical Therapeutics</i> , 2003 , 25 Suppl B, B64-80	3-5	25
291	Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. <i>Clinical Therapeutics</i> , 2003 , 25, 2991-3026	3-5	131
290	Ezetimibe: a novel option for lowering cholesterol. 2003 , 1, 11-21		30
289	Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes. 2003 , 5, 685-93		2
288	Potential therapeutic agents that raise high-density lipoprotein cholesterol levels. 2003 , 13, 167-175		1
287	Early combination therapy with a thiazolidinedione for the treatment of type 2 diabetes. 2003 , 29, 954-8, 961		2
286	Current therapeutic options in type 2 diabetes mellitus: a practical approach. 2003 , 1, 189-200		60

285	Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin. 2003 , 26, 269-73		74
284	Thiazolidinediones and blood lipids in type 2 diabetes. 2003 , 23, 1744-9		149
283	Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. 2003 , 163, 2594-602		211
282	Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. 2003 , 34, 1431-6		64
281	Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. 2003 , 111, 405-14		104
280	Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. <i>Endocrine Practice</i> , 2003 , 9, 406-16	3.2	142
279	Effects of pioglitazone on diabetes-related outcomes in Hispanic patients. 2003 , 60, 469-73		4
278	Insulin: thoroughly modern therapy. <i>Endocrine Practice</i> , 2004 , 10, 289-90	3.2	
277	Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. 2004 , 181, 536-539		63
276	A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. 2004 , 164, 2097-104		224
275	Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. 2004 , 20, 919-30		20
274	Durability of glycemic control: a feature of the thiazolidinediones. 2004 , 6, 179-89		4
273	Peroxisome proliferator-activated receptor ligands in atherosclerosis. 2004 , 13, 1393-403		7
272	One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. 2004 , 27, 141-7		188
271	Improved glycemic control without weight gain using triple therapy in type 2 diabetes. 2004 , 27, 1577-83		51
270	The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. 2004 , 27, 1647-53		196
269	Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones. 2004 , 6, 719-31		13
268	Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. 2004 , 50, 1184-8		118

267	Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. 2004 , 27, 41-6	84
266	Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. 2004 , 1, 44-50	36
265	Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. 2004 , 89, 6068-76	231
264	Lipids and lipoproteins in patients with type 2 diabetes. 2004 , 27, 1496-504	483
263	Economic benefits of pioglitazone for treating patients with Type 2 diabetes. 2004 , 4, 135-42	
262	Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies. 2004 , 58, 907-12	12
261	Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. 2004 , 58, 192-200	30
260	Treatment of insulin resistance in diabetes mellitus. 2004 , 490, 135-46	59
259	[Future targets in the treatment of type 2 diabetes]. 2004 , 116, 217-29	3
258	Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia. 2004 , 6, 81-93	13
257	Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. 2004 , 20, 215-23	42
256	Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective. 2004 , 22, 321-41	22
255	Dyslipidemia in type 2 diabetes. 2004 , 88, 897-909, x	67
254	[Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data]. 2004 , 65, 136-48	4
253	[Criteria and guidelines for combined therapy of type 2 diabetes. 2004 consensus document]. 2004 , 123, 187-97	3
252	[Heart, diabetes and glitazones]. 2004 , 65, S26-35	0
251	Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. 2004 , 20, 723-8	19
250	The role of sulphonylureas in the management of type 2 diabetes mellitus. 2004 , 64, 1339-58	216

249	Thiazolidinediones. 2004 , 351, 1106-18		1697
248	Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. 2004 , 6, 850-63		76
247	Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus. 2004 , 21, 259-71		24
246	Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. <i>Clinical Therapeutics</i> , 2004 , 26, 1400-10	3.5	45
245	The stepwise approach to the management of type 2 diabetes. 2004 , 65 Suppl 1, S3-8		53
244	[Cardiovascular effects of rosiglitazone]. 2004 , 33, 735-45		9
243	[The place of thiazolidinediones in the treatment of type 2 diabetes]. 2004 , 33, 1034-40		6
242	Clinical interest of PPARs ligands. 2004 , 30, 7-12		85
241	A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. <i>Clinical Therapeutics</i> , 2004 , 26, 805-18	3.5	44
240	Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. 2004 , 286, E116-22		78
239	Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin. 2005 , 44, 832-7		8
238	Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. 2005 , 7, 654-65		122
237	Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. 2005 , 7, 675-91		92
236	Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. 2005 , 22, 963-72		40
235	Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes. 2005 , 59, 1131-6		20
234	Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. 2005 , 59, 134-42		5
233	Thiazolidinediones-benefits on microvascular complications of type 2 diabetes. 2005 , 19, 168-77		16
232	Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. 2005 , 21, 167-74		132

231	Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. 2005 , 48, 1093-104		136
230	Rational drug design and PPAR agonists. 2005 , 5, 340-5		10
229	Oral Agents for Type 2 Diabetes: An Update. <i>Clinical Diabetes</i> , 2005 , 23, 64-76	2.9	40
228	Pioglitazone [An oral antidiabetic agent and metabolic syndrome modulator. Can theory translate into practice?]. 2005 , 5, 209-216		3
227	Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. 2005 , 44, 126-9		76
226	Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. 2005 , 3, 147-73		3
225	Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. 2005 , 28, 1680-9		77
224	Diabetes and cardiovascular risk markers. 2005 , 21 Suppl 1, S21-8		22
223	Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. 2005 , 46, 773-8		99
222	Receptores activados por proliferadores peroxisómicos tipo gamma en el síndrome metabólico: ¿amigos o enemigos?. 2005 , 17, 59-69		
221	Metformin monotherapy for type 2 diabetes mellitus. 2005 , CD002966		156
220	[Pioglitazone. Review of its metabolic and systemic effects]. 2005 , 205, 610-20		0
219	Données cliniques nouvelles sur les glitazones. 2005 , 66, 45-58		4
218	Potential cardiovascular benefits of insulin sensitizers. 2005 , 34, 117-35		10
217	PPARgamma and atherosclerosis. 2005 , 21 Suppl 1, S13-20		59
216	Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. 2005 , 21, 163-72		19
215	Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. 2005 , 68, 167-75		37
214	Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients. 2005 , 70, 193-4		9

213	Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. 2005 , 70, 53-62	59
212	The importance of tight glycaemic control. 2005 , 118, 75-115	69
211	Drug interactions of clinical importance with antihyperglycaemic agents: an update. 2005 , 28, 601-31	99
210	Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. 2005 , 65, 1-13	61
209	Pioglitazone Improves Diabetic Dyslipidaemia in Patients with Type 2 Diabetes Mellitus with or without Lipid-Lowering Therapy. 2005 , 25, 341-5	3
208	Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes. 2005 , 23, 119-38	13
207	Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus. 2005 , 4, 205-20	11
206	Diabetic dyslipidaemia: insights for optimizing patient management. 2005 , 21 Suppl 1, S29-40	24
205	Spotlight on pioglitazone in type 2 diabetes mellitus. 2006 , 5, 189-91	2
204	Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. 2006 , 4, 445-59	34
203	Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review. 2006 , 24, 425-41	37
202	Metformin and pioglitazone: Effectively treating insulin resistance. 2006 , 22 Suppl 2, S27-37	35
201	Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality. 2006 , 7, 463-76	15
200	Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. 2006 , 105, 743-52	31
199	Pioglitazone: a review of its use in type 2 diabetes mellitus. 2006 , 66, 85-109	112
198	Pioglitazone/metformin. 2006 , 66, 1863-77; discussion 1878-80	11
197	Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. 2006 , 22, 751-9	61
196	Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. 2006 , CD002967	81

195	Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. 2006 , 149, 845-849	36
194	A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control. 2006 , 22 Suppl 2, S39-48	10
193	Type 2 Diabetes. 2006 ,	
192	Pioglitazone for type 2 diabetes mellitus. 2006 , CD006060	35
191	Pioglitazone/Metformin (Actoplus met). 2006 , 108, 196-198	
190	Comparative Study of Thiazolidinediones in Clinical Use. 2006 , 16, 271-278	
189	Metabolic Syndrome. 2006 ,	
188	Pioglitazone and reductions in post-challenge glucose levels in patients with type 2 diabetes. 2006 , 8, 31-8	8
187	Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. 2006 , 8, 164-74	37
186	Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. 2006 , 8, 156-63	46
185	Thiazolidinediones, insulin resistance and obesity: Finding a balance. 2006 , 60, 1272-80	52
184	Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. 2006 , 36, 231-5	20
183	Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. 2006 , 260, 125-33	18
182	Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. 2006 , 26, 1388-95	32
181	Cardiovascular effects of the thiazolidinediones. 2006 , 22, 88-97	19
180	Can thiazolidinediones delay disease progression in type 2 diabetes?. 2006 , 22, 1193-201	11
179	Obesity and Diabetes. 2006 ,	4
178	Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (γ) Peroxisome Proliferator-Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A double-blind, randomized, pioglitazone-comparative study. 2006 , 22, 1016-1023	121

177	The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study. 2006 , 22, 343-50		18
176	Summarising the use of thiazolidinediones with insulin. 2007 , 7, 75-80		
175	Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes. 2007 , 23, 1775-81		9
174	beta-cell failure in diabetes and preservation by clinical treatment. 2007 , 28, 187-218		556
173	Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitus. 2007 , 2, 303-312		1
172	Oral antidiabetic drugs: bioavailability assessment of fixed-dose combination tablets of pioglitazone and metformin. Effect of body weight, gender, and race on systemic exposures of each drug. 2007 , 47, 37-47		15
171	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. <i>Endocrine Practice</i> , 2007 , 13 Suppl 1, 1-68	3.2	446
170	Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. 2007 , 30, 1979-87		422
169	Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. 2007 , 27, 2428-34		32
168	Pioglitazone in the management of Type 2 diabetes and beyond. 2007 , 4, 517-533		3
167	A 74-year-old woman with diabetes. 2007 , 297, 196-204		12
166	Thiazolidinediones and the risk of edema: a meta-analysis. 2007 , 76, 279-89		85
165	Traitement m̃dicamenteux du diab̃te de type 2recommandation de bonne pratique. 2007 , 33, S26-S105		5
164	Oral antidiabetic drugs: effect of food on absorption of pioglitazone and metformin from a fixed-dose combination tablet. 2007 , 47, 48-55		9
163	Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. 2007 , 9, 387-98		13
162	When and how to restore βcell function?. 2007 , 1303, 138-145		1
161	Post-Myocardial Infarction. 2007 ,		
160	Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2007 ,		4.9

159	Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. <i>Endocrine Practice</i> , 2007 , 13, 260-8	3-2	57
158	Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2007 , Volume 3, 503-510	4-4	13
157	beta-cell function and anti-diabetic pharmacotherapy. 2007 , 23, 518-27		61
156	A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes. 2007 , 24, 618-25		15
155	Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels. 2007 , 21 Suppl 2, 15-8		6
154	Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes. 2007 , 61, 1160-9		6
153	Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. 2008 , 45, 23-30		22
152	Impact of therapeutic advances on hypoglycaemia in type 2 diabetes. 2008 , 24, 257-85		11
151	Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. 2008 , 22, 247-64		32
150	Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. 2008 , 10, 617-25		14
149	Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. 2008 , 10, 626-37		19
148	Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. 2008 , 10, 699-718		38
147	Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. 2008 , 10, 1221-38		65
146	Tratamiento combinado de la diabetes mellitus tipo 2. 2008 , 15, 159-170		
145	Metformina. 2008 , 55, 39-52		
144	Metformin therapy and clinical uses. 2008 , 5, 157-67		200
143	The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. 2008 , 18, 373-9		12
142	Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. 2008 , 79, 196-203		52

141	2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. 2008 , 79, 453-60		26
140	[Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus]. 2008 , 131, 721-30		3
139	Les glitazones sont-elles toutes identiques?. 2008 , 2, 288-290		
138	Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?. 2008 , 9, 405-20		19
137	Preserving insulin secretion in Type 2 diabetes mellitus. 2008 , 3, 147-159		4
136	Targeting the pathophysiology of type 2 diabetes: rationale for combination therapy with pioglitazone and exenatide. 2008 , 24, 3009-22		9
135	Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. 2008 , 15, 506-11		24
134	Managing Type 2 Diabetes: Going Beyond Glycemic Control. 2008 , 14, 1-22		3
133	Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. <i>Vascular Health and Risk Management</i> , 2008 , 4, 297-304	4-4	82
132	Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. 2008 , 15, 34-40		18
131	Risk management in the treatment of type 2 diabetes with pioglitazone. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2009 , Volume 2, 51-60	3-4	
130	Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. 2009 , 102, 67-76		26
129	Redefining the role of thiazolidinediones in the management of type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2009 , 5, 141-51	4-4	42
128	Safety and Efficacy of Pioglitazone/Metformin Combination Therapy in Treatment of Type 2 Diabetes: A Rationale for Earlier Use. 2009 , 1, CMT.S2370		
127	Metformin: A Review of Its Use in the Treatment of Type 2 Diabetes. 2009 , 1, CMT.S1085		1
126	Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. 2009 , 25, 1111-9		22
125	Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study. 2009 , 3, 1442-50		3
124	Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions. 2009 , 11, 379-83		5

123	Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. 2009 , 117, 522-57		74
122	Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. 2009 , 75, 961-8		42
121	Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. 2009 , 4, 32-64		44
120	Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. 2009 , 63, 912-29		30
119	Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes. 2009 , 63, 1354-68		3
118	The role of pioglitazone in modifying the atherogenic lipoprotein profile. 2009 , 11, 742-56		22
117	Earlier triple therapy with pioglitazone in patients with type 2 diabetes. 2009 , 11, 844-54		20
116	Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. 2009 , 11, 1091-9		36
115	The backbone of oral glucose-lowering therapy: time for a paradigm shift?. 2009 , 23, 651-67		
114	LCMSMS Development and Validation for Simultaneous Quantitation of Metformin, Glimepiride and Pioglitazone in Human Plasma and Its Application to a Bioequivalence Study. 2009 , 69, 1243-1250		46
113	Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. 2009 , 174, 2007-14		27
112	Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. 2009 , 58, 773-95		1832
111	Diabetes medications and body weight. 2009 , 8, 573-84		93
110	Treatment of type 2 diabetes mellitus with orally administered agents: advances in combination therapy. <i>Endocrine Practice</i> , 2009 , 15, 750-62	3.2	4
109	Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. <i>Clinical Therapeutics</i> , 2010 , 32, 1408-18	3.5	8
108	EVITA: a tool for the early evaluation of pharmaceutical innovations with regard to therapeutic advantage. 2010 , 10, 5		10
107	Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study. 2010 , 16, 1124-8		25
106	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , Volume 3, 243-252	3.4	3

105	The continuation of oral medications with the initiation of insulin therapy in type 2 diabetes: a review of the evidence. 2010 , 103, 58-65	13
104	Diabetes Mellitus. 2010 , 760-774	2
103	Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review. 2010 , 3, 43-51	9
102	THE IMPACT OF PIOGLITAZONE THERAPY ON GLYCEMIC CONTROL, BLOOD PRESSURE AND INFLAMMATORY MARKERS IN PATIENTS WITH DIABETES MELLITUS. 2010 , 6, 73-82	
101	Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells. 2010 , 51, 2211-22	21
100	Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. 2010 , CD002967	162
99	Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. 2010 , CD002967	194
98	Natural products for type II diabetes treatment. 2010 , 71, 21-73	43
97	Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. 2010 , 70, 1945-61	51
96	Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies. 2010 , 123, S2-S10	26
95	Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA). 2011 , 27, 303-13	12
94	Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. 2011 , 11, 115-28	128
93	Pioglitazone is a valid alternative to rosiglitazone. 2011 , 11, 357-62	10
92	Add-on therapies to metformin for type 2 diabetes. 2011 , 12, 47-62	14
91	Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?. 2011 , 124, S19-34	54
90	Thiazolidinediones plus metformin association on body weight in patients with type 2 diabetes. 2011 , 91, 265-70	19
89	The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. 2011 , 32, 607-16	69
88	Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. 2011 , 6, e29052	34

87	Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β -cell function in patients with type 2 diabetes. 2011 , 65, 154-64		46
86	Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886. 2011 , 668, 486-91		9
85	Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study. <i>Cardiovascular Diabetology</i> , 2011 , 10, 18	8.7	9
84	Combination lipid therapy in type 2 diabetes mellitus. 2011 , 12, 1393-403		1
83	Comparison of the effects of long-term pioglitazone and rosiglitazone therapy on liver enzymes in type 2 diabetes. 2011 , 11, 121-129		1
82	Review of approved pioglitazone combinations for type 2 diabetes. 2011 , 12, 1571-84		9
81	Evaluation of the bioequivalence of a fixed-dose combination tablet of pioglitazone/metformin versus commercial tablets in healthy Japanese male volunteers. 2012 , 2, 13-20		1
80	Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. 2012 , 28, 1213-20		11
79	Metformin and its clinical use: new insights for an old drug in clinical practice. 2012 , 8, 907-17		58
78	AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: a summary of the key findings. 2012 , 18, 1-22		7
77	Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study. 2012 , 14, 745-52		30
76	Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. 2012 , 14, 810-20		126
75	Putting medications where they belong: practical advice for managing type 2 diabetes in clinical practice. 2013 , 25, 65-76		1
74	Differential sensitivities of the vascular K(ATP) channel to various PPAR activators. 2013 , 85, 1495-503		2
73	Pharmacoth�apie du diab�ete de type 2. 2013 , 37, S428-S436		1
72	The Metabolic Syndrome. 2013 ,		6
71	Development and Discovery Avenues in Bioactive Natural Products for Glycemic Novel Therapeutics. 2013 , 39, 431-466		6
70	Pioglitazona en el control gluc�mico, perfil lip�dico y riesgo cardiovascular: revisi�n actualizada sobre sus beneficios y datos emergentes sobre su seguridad. 2013 , 29, 1-12		

69	Pharmacologic management of type 2 diabetes. 2013 , 37 Suppl 1, S61-8	101
68	Treatment with Thiazolidinediones. 2013 , 117-146	
67	Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. 2013 , 41, 132-47	20
66	In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. 2013 , 36 Suppl 2, S162-74	72
65	Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. 2013 , 36 Suppl 2, S127-38	179
64	Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial. 2013 , 4, 27-32	23
63	Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. <i>Journal of Diabetes Investigation</i> , 2013 , 4, 517-24	3.9 30
62	Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS). 2013 , 12, 363-78	18
61	Peroxisome proliferator-activated receptor activating hypoglycemic effect of <i>Gardenia jasminoides</i> Ellis aqueous extract and improvement of insulin sensitivity in steroid induced insulin resistant rats. 2014 , 14, 30	20
60	Controversies in Obesity. 2014 ,	1
59	Gastro-floating bilayer tablets for the sustained release of metformin and immediate release of pioglitazone: preparation and in vitro/in vivo evaluation. 2014 , 476, 223-31	29
58	WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus. 2015 , CD002966	1
57	Polemics of pioglitazone: an appraisal in 2015. 2015 , 10, 447-458	0
56	Pharmacologic treatment of type 2 diabetes: oral medications. 2015 , 49, 540-56	54
55	Combination therapy in type 2 diabetes mellitus. 2015 , 686-708	1
54	PPAR agonists in the treatment of diabetes. 2015 , 657-672	
53	Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement. 2015 , 68, 200-10	4
52	Hydroxyoctadecadienoic acids: Oxidised derivatives of linoleic acid and their role in inflammation associated with metabolic syndrome and cancer. 2016 , 785, 70-76	65

51	Type 2 Diabetes. 2016 ,			2
50	Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. 2017 , 5, e000364			12
49	Metformin: clinical use in type 2 diabetes. 2017 , 60, 1586-1593			170
48	Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin. 2017 , 5, 955-962			3
47	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Journal of Diabetes Investigation</i> , 2018 , 9, 657	3.9		136
46	The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. 2018 , 233, 153-161			96
45	Pharmacotherapy of type 2 diabetes: An update. 2018 , 78, 13-42			103
44	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. 2018 , 9, CD011798			27
43	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 2018 , 61, 2461-2498			656
42	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 2018 , 41, 2669-2701			1307
41	SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. 2018 , 41, 1543-1556			99
40	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Diabetology International</i> , 2018 , 9, 1-45	2.3		114
39	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. 2019 , 16, 133-143			63
38	Pioglitazone Improves the Function of Human Mesenchymal Stem Cells in Chronic Kidney Disease Patients. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3		8
37	Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. <i>Diabetology International</i> , 2019 , 10, 24-36	2.3		12
36	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Journal of Diabetes Investigation</i> , 2020 , 11, 1020-1076	3.9		46
35	Japanese Clinical Practice Guideline for Diabetes 2019. <i>Diabetology International</i> , 2020 , 11, 165-223	2.3		75
34	Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). <i>Cardiovascular Diabetology</i> , 2020 , 19, 93	8.7		16

33	Co-administration with Obestatin Reduces Accumulation of Subcutaneous Fat Due to Rosiglitazone Administration in DIO-C57BL/6 Mice. <i>International Journal of Peptide Research and Therapeutics</i> , 2020 , 26, 2307-2315	2.1	3
32	A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone. <i>Perspectives in Clinical Research</i> , 2021 , 12, 9-13	1.4	1
31	Anti-diabetic Potentials of Thiazolidinedione Analogues with Efficient Synthetic Procedures: A Review of Literature. <i>Mini-Reviews in Organic Chemistry</i> , 2021 , 18,	1.7	
30	Metformin and Other Biguanides: Pharmacology and Therapeutic Usage.		1
29	Thiazolidinediones as PPAR Agonists.		1
28	Combination Therapy in Type 2 Diabetes.		2
27	Qualität der Arzneimittelversorgung. 2003 , 832-852		1
26	Glycemic Management. <i>Endocrine Practice</i> , 2007 , 13, 16-34	3.2	3
25	Risk management in the treatment of type 2 diabetes with pioglitazone. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2009 , 2, 51-60	3.4	1
24	Neue Arzneimittel. 2001 , 23-71		
23	Are Thiazolidinediones Superior to Standard Therapy in the Treatment of Type 2 Diabetes?. <i>Medical Science Symposia Series</i> , 2002 , 149-155		
22	Potential of glitazones in diabetes. 2002 , 69-84		
21	The Glitazones, Lessons so Far. 2007 , 87-97		
20	Thiazolidinediones. 2007 , 135-157		
19	Combination Therapy for Treatment of Type 2 Diabetes. 2007 , 207-226		
18	Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 Diabetes Mellitus. <i>Pharmacy Practice</i> , 2008 , 6, 79-87	1.8	
17	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010 , 3, 243-52	3.4	
16	How to use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 494-513		

15	Thiazolidinediones: a long way to clinical practice. <i>Problemy Endokrinologii</i> , 2011 , 57, 57-63	0	
14	Weight Gain on Glucose-Lowering Agents. 2014 , 263-277		
13	Cognitive Impairment in Type 2 Diabetic Patients Treated with Metformin in Comparison with those Taking Glibenclamide. <i>Journal of Neurology & Stroke</i> , 2014 , 1,	0.7	
12	ECCELL FAILURE AND PRESERVATION IN TYPE 2 DIABETES MELLITUS: A REVIEW. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2016 , 5, 5315-5321	0.1	
11	Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Therapy in Treating Patients with Newly Diagnosed T2DM. <i>Advances in Clinical Medicine</i> , 2020 , 10, 1869-1873	0	
10	Treatment of the Obese Patients With Type 2 Diabetes. 2006 , 471-486		
9	Management of type 2 diabetes mellitus. Role of thiazolidinediones. <i>Canadian Family Physician</i> , 2005 , 51, 683-7	0.9	12
8	Advances in diabetes for the millennium: drug therapy of type 2 diabetes. <i>MedGenMed: Medscape General Medicine</i> , 2004 , 6, 9		5
7	A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2007 , 3, 721-31	4.4	4
6	Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes. <i>Vascular Health and Risk Management</i> , 2007 , 3, 503-10	4.4	8
5	Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2008 , 2, 189-98	4.9	3
4	Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. <i>Open Medicine</i> , 2011 , 5, e35-48		50
3	Palmitate-induced insulin resistance is attenuated by Pioglitazone and EGCG through reducing the gluconeogenic key enzymes expression in HepG2 cells. <i>Journal of Medicine and Life</i> , 2017 , 10, 244-249	1.5	5
2	Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes.. <i>Clinical Diabetes</i> , 2022 , 40, 97-107	2.9	1
1	Polypharmacology in Clinical Applications: Metabolic Disease Polypharmacology. 2022 , 199-229		